AU2002220008A1 - Antisense modulation of mp-1 expression - Google Patents
Antisense modulation of mp-1 expressionInfo
- Publication number
- AU2002220008A1 AU2002220008A1 AU2002220008A AU2000802A AU2002220008A1 AU 2002220008 A1 AU2002220008 A1 AU 2002220008A1 AU 2002220008 A AU2002220008 A AU 2002220008A AU 2000802 A AU2000802 A AU 2000802A AU 2002220008 A1 AU2002220008 A1 AU 2002220008A1
- Authority
- AU
- Australia
- Prior art keywords
- expression
- antisense modulation
- antisense
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/721,822 | 2000-11-22 | ||
US09/721,822 US6306606B1 (en) | 2000-11-22 | 2000-11-22 | Antisense modulation of MP-1 expression |
PCT/US2001/045178 WO2002042425A2 (en) | 2000-11-22 | 2001-11-20 | Antisense modulation of mp-1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002220008A1 true AU2002220008A1 (en) | 2002-06-03 |
Family
ID=24899446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002220008A Abandoned AU2002220008A1 (en) | 2000-11-22 | 2001-11-20 | Antisense modulation of mp-1 expression |
Country Status (3)
Country | Link |
---|---|
US (1) | US6306606B1 (en) |
AU (1) | AU2002220008A1 (en) |
WO (1) | WO2002042425A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030232438A1 (en) * | 2002-06-17 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of KOX 1 expression |
US20040110700A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of CD1D expression |
WO2005071080A2 (en) * | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US20070172843A1 (en) * | 2005-09-12 | 2007-07-26 | Conrad Susan E | MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2000
- 2000-11-22 US US09/721,822 patent/US6306606B1/en not_active Expired - Lifetime
-
2001
- 2001-11-20 WO PCT/US2001/045178 patent/WO2002042425A2/en not_active Application Discontinuation
- 2001-11-20 AU AU2002220008A patent/AU2002220008A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002042425A3 (en) | 2002-09-06 |
WO2002042425A2 (en) | 2002-05-30 |
US6306606B1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU2001289046A1 (en) | Antisense modulation of her-2 expression | |
AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
AU2001261808A1 (en) | Antisense modulation of pten expression | |
AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
AU2001263171A1 (en) | Antisense modulation of tert expression | |
AU2001239971A1 (en) | Antisense modulation of parp expression | |
AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
AU6115400A (en) | Antisense modulation of mekk5 expression | |
AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
AU2001288968A1 (en) | Antisense modulation of btak expression | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
AU2002226064A1 (en) | Antisense modulation of talin expression | |
AU2001234462A1 (en) | Antisense modulation of cot oncogene expression | |
AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
AU1244901A (en) | Antisense modulation of rank expression | |
AU2410600A (en) | Antisense modulation of g-alpha-i3 expression |